{"component": "clause", "props": {"groups": [{"size": 6, "snippet_links": [{"key": "been-omitted-from-this-exhibit", "type": "clause", "offset": [16, 46]}, {"key": "not-material", "type": "clause", "offset": [66, 78]}, {"key": "publicly-disclosed", "type": "definition", "offset": [140, 158]}], "snippet": "INFORMATION HAS BEEN OMITTED FROM THIS EXHIBIT BECAUSE IT IS BOTH NOT MATERIAL AND WOULD LIKELY CAUSE COMPETITIVE HARM TO THE REGISTRANT IF PUBLICLY DISCLOSED. OMISSIONS ARE IDENTIFIED AS [***]", "samples": [{"hash": "6w0E2tStRUF", "uri": "/contracts/6w0E2tStRUF#certain-identified", "label": "License and Research Collaboration Agreement (Opko Health, Inc.)", "score": 34.3333333333, "published": true}, {"hash": "gSDdkn6oTtO", "uri": "/contracts/gSDdkn6oTtO#certain-identified", "label": "License Agreement (Opko Health, Inc.)", "score": 32.5728952772, "published": true}, {"hash": "fn6K9fPZIjt", "uri": "/contracts/fn6K9fPZIjt#certain-identified", "label": "Exclusive License Agreement (Opko Health, Inc.)", "score": 32.5728952772, "published": true}], "hash": "26e87ded4926e7d6120d90ced4d15745", "id": 1}, {"size": 3, "snippet_links": [{"key": "not-material", "type": "clause", "offset": [67, 79]}, {"key": "publicly-disclosed", "type": "definition", "offset": [141, 159]}, {"key": "first-amendment-to-license-agreement", "type": "clause", "offset": [238, 274]}, {"key": "entered-into", "type": "clause", "offset": [306, 318]}, {"key": "amendment-effective-date", "type": "definition", "offset": [345, 369]}, {"key": "trustees-of", "type": "definition", "offset": [438, 449]}, {"key": "city-of-new-york", "type": "definition", "offset": [477, 493]}], "snippet": "INFORMATION HAS BEEN OMITTED FROM THIS DOCUMENT BECAUSE IT IS BOTH NOT MATERIAL AND WOULD LIKELY CAUSE COMPETITIVE HARM TO THE REGISTRANT IF PUBLICLY DISCLOSED, AND HAS BEEN MARKED \u201c[***]\u201d TO INDICATE WHERE OMISSIONS HAVE BEEN MADE. This FIRST AMENDMENT TO LICENSE AGREEMENT (this \u201cAmendment\u201d) is made and entered into as of September 7, 2016 (\u201cAmendment Effective Date\u201d) by and between Singular Genomics Systems Inc. (\u201cCompany\u201d) and The Trustees of Columbia University in the City of New York (\u201cColumbia\u201d).", "samples": [{"hash": "3q7f9Y9A9sL", "uri": "/contracts/3q7f9Y9A9sL#certain-identified", "label": "Exclusive License Agreement (Singular Genomics Systems, Inc.)", "score": 32.3456536619, "published": true}], "hash": "dad9731c070f14ef11582edc4edfa5cc", "id": 2}, {"size": 2, "snippet_links": [], "snippet": "INFORMATION HAS", "samples": [{"hash": "36z7d0Yuxov", "uri": "/contracts/36z7d0Yuxov#certain-identified", "label": "Master Agreement (Nuvo Group Ltd.)", "score": 32.8932238193, "published": true}, {"hash": "hSqIevZvHog", "uri": "/contracts/hSqIevZvHog#certain-identified", "label": "Development and Commercialization License Agreement (Opko Health, Inc.)", "score": 31.5790554415, "published": true}], "hash": "9da196f6408fd1d66c8da46e8544fcf4", "id": 3}, {"size": 2, "snippet_links": [{"key": "this-exhibit", "type": "definition", "offset": [35, 47]}, {"key": "not-material", "type": "clause", "offset": [66, 78]}, {"key": "would-be-competitively-harmful-if-publicly-disclosed", "type": "clause", "offset": [88, 140]}, {"key": "excluded-information", "type": "definition", "offset": [147, 167]}, {"key": "shareholders-agreement", "type": "definition", "offset": [205, 227]}, {"key": "march-2023", "type": "clause", "offset": [260, 270]}, {"key": "limited-liability-company", "type": "definition", "offset": [301, 326]}, {"key": "the-laws", "type": "definition", "offset": [346, 354]}, {"key": "commercial-register", "type": "definition", "offset": [387, 406]}, {"key": "register-number", "type": "definition", "offset": [446, 461]}, {"key": "registered-office", "type": "definition", "offset": [479, 496]}, {"key": "holdings-1", "type": "definition", "offset": [887, 897]}, {"key": "the-investor", "type": "definition", "offset": [1187, 1199]}, {"key": "and-the-company", "type": "clause", "offset": [1200, 1215]}], "snippet": "INFORMATION HAS BEEN EXCLUDED FROM THIS EXHIBIT BECAUSE IT (I) IS NOT MATERIAL AND (II) WOULD BE COMPETITIVELY HARMFUL IF PUBLICLY DISCLOSED. SUCH EXCLUDED INFORMATION HAS BEEN MARKED WITH \u201c[***]\u201d. 1 This Shareholders Agreement (the \u201cAgreement\u201d) is made on 22 March 2023 between: (1) Vodafone GmbH, a limited liability company incorporated under the laws of Germany, registered with the commercial register of the local court of D\u00fcsseldorf under register number HRB 38062, whose registered office is at \u2587\u2587\u2587\u2587\u2587\u2587\u2587\u2587\u2587-\u2587\u2587\u2587\u2587\u2587-\u2587\u2587\u2587\u2587\u2587 \u2587, \u2587\u2587\u2587\u2587\u2587 \u2587\u2587\u2587\u2587\u2587\u2587\u2587\u2587\u2587\u2587, \u2587\u2587\u2587\u2587\u2587\u2587\u2587 (\u201cVodafone\u201d); (2) Oak Consortium GmbH, a limited liability company incorporated under the laws of Germany, registered with the commercial register of the local court of Munich under register number HRB 278102, whose registered office is at \u2587\u2587\u2587\u2587\u2587\u2587\u2587\u2587\u2587\u2587\u2587\u2587\u2587 \u2587\u2587\u2587\u2587\u2587\u2587\u2587\u2587\u2587\u2587\u2587 \u2587\u2587, \u2587\u2587\u2587\u2587\u2587 \u2587\u2587\u2587\u2587\u2587\u2587\u2587\u2587\u2587 \u2587\u2587 \u2587\u2587\u2587\u2587, \u2587\u2587\u2587\u2587\u2587\u2587\u2587 (the \u201cInvestor\u201d); and (3) Oak Holdings 1 GmbH, a limited liability company incorporated under the laws of Germany, registered with the commercial register of the local court of D\u00fcsseldorf under register number HRB 98913, whose registered office is at \u2587\u2587\u2587\u2587\u2587\u2587\u2587\u2587\u2587-\u2587\u2587\u2587\u2587\u2587-\u2587\u2587\u2587\u2587\u2587 \u2587, \u2587\u2587\u2587\u2587\u2587 \u2587\u2587\u2587\u2587\u2587\u2587\u2587\u2587\u2587\u2587, \u2587\u2587\u2587\u2587\u2587\u2587\u2587, (the \u201cCompany\u201d); Vodafone, the Investor and the Company are also collectively referred to as \u201cParties\u201d and each of them as a \u201cParty\u201d.", "samples": [{"hash": "1nrSMStSksO", "uri": "/contracts/1nrSMStSksO#certain-identified", "label": "Shareholders\u2019 Agreement (Vodafone Group Public LTD Co)", "score": 32.4674880219, "published": true}], "hash": "3195edf72c993f76b99630a38b8c876f", "id": 4}, {"size": 1, "snippet_links": [{"key": "not-material", "type": "clause", "offset": [67, 79]}, {"key": "publicly-disclosed", "type": "definition", "offset": [141, 159]}, {"key": "respective-affiliates", "type": "definition", "offset": [246, 267]}, {"key": "engaged-in", "type": "definition", "offset": [269, 279]}, {"key": "activities-under-this-agreement", "type": "clause", "offset": [291, 322]}, {"key": "joint-patent", "type": "definition", "offset": [325, 337]}, {"key": "each-party-will", "type": "clause", "offset": [341, 356]}, {"key": "other-party", "type": "definition", "offset": [382, 393]}, {"key": "invention-disclosures", "type": "definition", "offset": [398, 419]}, {"key": "independent-contractors", "type": "definition", "offset": [493, 516]}, {"key": "all-information", "type": "clause", "offset": [581, 596]}, {"key": "necessary-for", "type": "definition", "offset": [597, 610]}, {"key": "maintenance-of", "type": "clause", "offset": [639, 653]}], "snippet": "INFORMATION HAS BEEN OMITTED FROM THIS DOCUMENT BECAUSE IT IS BOTH NOT MATERIAL AND WOULD LIKELY CAUSE COMPETITIVE HARM TO THE REGISTRANT IF PUBLICLY DISCLOSED, AND HAS BEEN MARKED WITH \u201c[***]\u201d TO INDICATE WHERE OMISSIONS HAVE BEEN MADE. (or its respective Affiliates) engaged in performing activities under this Agreement (\u201cJoint Patent\u201d), each Party will promptly disclose to the other Party any invention disclosures, or other similar documents, submitted to it by its employees, agents or independent contractors describing the Invention(s) to be disclosed in such Patent, and all information necessary for the preparation, filing and maintenance of any such Joint Patent.", "samples": [{"hash": "4L4MdkCpHRq", "uri": "/contracts/4L4MdkCpHRq#certain-identified", "label": "License Agreement (Contineum Therapeutics, Inc.)", "score": 34.9466119097, "published": true}], "hash": "f0fdf8b6a24059a855191c07df6504e3", "id": 5}, {"size": 1, "snippet_links": [{"key": "this-exhibit", "type": "definition", "offset": [35, 47]}, {"key": "not-material", "type": "clause", "offset": [66, 78]}, {"key": "would-be-competitively-harmful-if-publicly-disclosed", "type": "clause", "offset": [88, 140]}, {"key": "excluded-information", "type": "definition", "offset": [147, 167]}], "snippet": "INFORMATION HAS BEEN EXCLUDED FROM THIS EXHIBIT BECAUSE IT (I) IS NOT MATERIAL AND (II) WOULD BE COMPETITIVELY HARMFUL IF PUBLICLY DISCLOSED. SUCH EXCLUDED INFORMATION HAS BEEN MARKED WITH \u201c[***]\u201d.", "samples": [{"hash": "fkfeMkBbZdi", "uri": "/contracts/fkfeMkBbZdi#certain-identified", "label": "Investment Agreement (Vodafone Group Public LTD Co)", "score": 32.4674880219, "published": true}], "hash": "fbb59517a3b15a61ddf5d40d6b4a78b2", "id": 6}, {"size": 1, "snippet_links": [{"key": "not-material", "type": "clause", "offset": [67, 79]}, {"key": "publicly-disclosed", "type": "definition", "offset": [141, 159]}, {"key": "with-a-copy-to", "type": "clause", "offset": [238, 252]}, {"key": "law-department", "type": "definition", "offset": [272, 286]}, {"key": "new-brunswick", "type": "clause", "offset": [315, 328]}, {"key": "general-counsel", "type": "clause", "offset": [350, 365]}, {"key": "other-communications", "type": "clause", "offset": [432, 452]}, {"key": "received-on", "type": "clause", "offset": [481, 492]}, {"key": "day-of", "type": "clause", "offset": [497, 503]}, {"key": "provided-that", "type": "clause", "offset": [514, 527]}, {"key": "in-accordance-with", "type": "definition", "offset": [558, 576]}, {"key": "section-136", "type": "clause", "offset": [604, 616]}], "snippet": "INFORMATION HAS BEEN OMITTED FROM THIS DOCUMENT BECAUSE IT IS BOTH NOT MATERIAL AND WOULD LIKELY CAUSE COMPETITIVE HARM TO THE REGISTRANT IF PUBLICLY DISCLOSED, AND HAS BEEN MARKED WITH \u201c[***]\u201d TO INDICATE WHERE OMISSIONS HAVE BEEN MADE. With a copy to: \u2587\u2587\u2587\u2587\u2587\u2587\u2587 & \u2587\u2587\u2587\u2587\u2587\u2587\u2587 Law Department One \u2587\u2587\u2587\u2587\u2587\u2587\u2587 & \u2587\u2587\u2587\u2587\u2587\u2587\u2587 Plaza New Brunswick, NJ 08933 Attention: General Counsel, Pharmaceuticals All such notices, requests, demands, waivers and other communications will be deemed to have been received on the day of delivery, provided that a copy is also sent by e-mail in accordance with the first sentence of this Section 13.6.", "samples": [{"hash": "4L4MdkCpHRq", "uri": "/contracts/4L4MdkCpHRq#certain-identified", "label": "License Agreement (Contineum Therapeutics, Inc.)", "score": 34.9466119097, "published": true}], "hash": "1ee2f43d2336b20260fc8f8a912b95f0", "id": 7}, {"size": 1, "snippet_links": [{"key": "not-material", "type": "clause", "offset": [67, 79]}, {"key": "publicly-disclosed", "type": "definition", "offset": [141, 159]}, {"key": "charge-backs", "type": "clause", "offset": [247, 259]}, {"key": "administrative-fees", "type": "definition", "offset": [261, 280]}, {"key": "or-equivalent", "type": "definition", "offset": [308, 321]}, {"key": "granted-to", "type": "definition", "offset": [340, 350]}, {"key": "health-care-organizations", "type": "clause", "offset": [359, 384]}, {"key": "group-purchasing", "type": "clause", "offset": [386, 402]}, {"key": "pharmacy-benefit-managers", "type": "definition", "offset": [428, 453]}, {"key": "pharmacy-providers", "type": "definition", "offset": [489, 507]}, {"key": "other-governments", "type": "definition", "offset": [545, 562]}, {"key": "trade-customers", "type": "definition", "offset": [613, 628]}, {"key": "each-case", "type": "definition", "offset": [633, 642]}, {"key": "with-respect-to", "type": "clause", "offset": [644, 659]}, {"key": "licensed-products", "type": "clause", "offset": [660, 677]}, {"key": "bad-debt", "type": "definition", "offset": [686, 694]}, {"key": "sale-of", "type": "clause", "offset": [734, 741]}, {"key": "sovereign-risk", "type": "definition", "offset": [851, 865]}, {"key": "for-customers", "type": "clause", "offset": [871, 884]}, {"key": "associated-with", "type": "definition", "offset": [943, 958]}, {"key": "to-the-extent", "type": "clause", "offset": [1071, 1084]}, {"key": "commercially-reasonable", "type": "clause", "offset": [1094, 1117]}, {"key": "in-the-ordinary-course-of-business", "type": "definition", "offset": [1186, 1220]}, {"key": "type-and-amount", "type": "clause", "offset": [1224, 1239]}, {"key": "consistent-with", "type": "clause", "offset": [1240, 1255]}, {"key": "the-case", "type": "definition", "offset": [1306, 1314]}, {"key": "business-practices", "type": "definition", "offset": [1323, 1341]}, {"key": "consistently-applied", "type": "definition", "offset": [1342, 1362]}, {"key": "product-lines", "type": "definition", "offset": [1374, 1387]}, {"key": "accounting-standards", "type": "definition", "offset": [1392, 1412]}, {"key": "other-deductions", "type": "clause", "offset": [1482, 1498]}, {"key": "allocated-to", "type": "definition", "offset": [1528, 1540]}, {"key": "other-products", "type": "definition", "offset": [1562, 1576]}, {"key": "affiliates-and-sublicensees", "type": "clause", "offset": [1596, 1623]}, {"key": "between-the-parties", "type": "clause", "offset": [1803, 1822]}, {"key": "respective-affiliates", "type": "definition", "offset": [1833, 1854]}, {"key": "sales-to-third-parties", "type": "clause", "offset": [1891, 1913]}, {"key": "end-user", "type": "definition", "offset": [2053, 2061]}, {"key": "determination-of-net", "type": "clause", "offset": [2099, 2119]}, {"key": "clinical-studies", "type": "clause", "offset": [2179, 2195]}, {"key": "disposition-of", "type": "clause", "offset": [2307, 2321]}, {"key": "free-samples", "type": "clause", "offset": [2346, 2358]}, {"key": "marketing-programs", "type": "definition", "offset": [2396, 2414]}, {"key": "compassionate-use", "type": "clause", "offset": [2498, 2515]}, {"key": "named-patient-sales", "type": "definition", "offset": [2521, 2540]}, {"key": "early-access-programs", "type": "clause", "offset": [2543, 2564]}, {"key": "the-parties-will", "type": "clause", "offset": [2689, 2705]}, {"key": "negotiate-in-good-faith", "type": "definition", "offset": [2706, 2729]}, {"key": "allocation-of-net-sales", "type": "clause", "offset": [2810, 2833]}, {"key": "licensed-compound", "type": "definition", "offset": [2891, 2908]}, {"key": "other-components", "type": "clause", "offset": [2945, 2961]}, {"key": "based-on", "type": "clause", "offset": [2984, 2992]}, {"key": "the-fair-market-value", "type": "clause", "offset": [2993, 3014]}, {"key": "for-the-purposes-of", "type": "clause", "offset": [3034, 3053]}, {"key": "licensed-api", "type": "definition", "offset": [3097, 3109]}, {"key": "related-to", "type": "clause", "offset": [3149, 3159]}, {"key": "this-agreement", "type": "clause", "offset": [3191, 3205]}, {"key": "royalty-payments", "type": "clause", "offset": [3217, 3233]}, {"key": "due-and-payable", "type": "clause", "offset": [3255, 3270]}, {"key": "without-limiting-the-foregoing", "type": "clause", "offset": [3311, 3341]}, {"key": "according-to", "type": "definition", "offset": [3436, 3448]}, {"key": "information-needed", "type": "clause", "offset": [3562, 3580]}, {"key": "not-available", "type": "definition", "offset": [3621, 3634]}, {"key": "combination-products", "type": "clause", "offset": [3662, 3682]}, {"key": "determination-of-royalties", "type": "clause", "offset": [3691, 3717]}, {"key": "sales-milestone-payments", "type": "clause", "offset": [3722, 3746]}, {"key": "price-of-the", "type": "clause", "offset": [3878, 3890]}, {"key": "contained-in", "type": "definition", "offset": [3918, 3930]}, {"key": "the-combination", "type": "clause", "offset": [3931, 3946]}, {"key": "subject-to", "type": "definition", "offset": [3978, 3988]}, {"key": "sum-of", "type": "clause", "offset": [4025, 4031]}, {"key": "selling-prices", "type": "definition", "offset": [4048, 4062]}, {"key": "certain-identified-information", "type": "clause", "offset": [4667, 4697]}, {"key": "total-number-of", "type": "definition", "offset": [5142, 5157]}, {"key": "product-components", "type": "definition", "offset": [5158, 5176]}, {"key": "parties-are", "type": "clause", "offset": [5300, 5311]}, {"key": "agreement-regarding", "type": "clause", "offset": [5328, 5347]}, {"key": "prior-to-launch", "type": "clause", "offset": [5373, 5388]}, {"key": "calculation-of", "type": "definition", "offset": [5421, 5435]}, {"key": "reasonable-discretion", "type": "definition", "offset": [5579, 5600]}, {"key": "in-clauses", "type": "clause", "offset": [5641, 5651]}, {"key": "selling-party", "type": "definition", "offset": [5918, 5931]}, {"key": "other-party", "type": "definition", "offset": [5961, 5972]}, {"key": "notify-the", "type": "clause", "offset": [6120, 6130]}, {"key": "allocation-notice", "type": "definition", "offset": [6155, 6172]}, {"key": "of-each-party", "type": "clause", "offset": [6206, 6219]}, {"key": "determine-the", "type": "clause", "offset": [6248, 6261]}, {"key": "the-applicable", "type": "clause", "offset": [6288, 6302]}, {"key": "do-not-agree", "type": "clause", "offset": [6330, 6342]}, {"key": "for-clarity", "type": "clause", "offset": [6423, 6434]}, {"key": "in-accordance-with", "type": "definition", "offset": [6637, 6655]}], "snippet": "INFORMATION HAS BEEN OMITTED FROM THIS DOCUMENT BECAUSE IT IS BOTH NOT MATERIAL AND WOULD LIKELY CAUSE COMPETITIVE HARM TO THE REGISTRANT IF PUBLICLY DISCLOSED, AND HAS BEEN MARKED WITH \u201c[***]\u201d TO INDICATE WHERE OMISSIONS HAVE BEEN MADE. rebates, charge backs, administrative fees, allowances and discounts (or equivalent thereof) actually granted to managed health care organizations, group purchasing organizations, insurers, pharmacy benefit managers (or equivalent thereof), specialty Pharmacy providers, federal, state/provincial, local or other governments, or their agencies or purchasers, reimbursers, or trade customers, in each case, with respect to Licensed Products; actual bad debt write-off attributable directly to the sale of such Licensed Product, any reserve or financial discount created for uncollectable amounts in countries with sovereign risk, and for customers whose DSO exceeds [***]; and coupons, or discount/rebates associated with co-pay cards, in each case, specific to Licensed Products. All aforementioned deductions will only be allowable to the extent they are commercially reasonable, and will be determined, on a country-by-country basis, as incurred in the ordinary course of business in type and amount consistent with \u2587\u2587\u2587\u2587\u2587\u2587\u2587\u2019\u2587 or its Affiliate\u2019s or sublicensee\u2019s (as the case may be) business practices consistently applied across its product lines and accounting standards and verifiable. All such discounts, allowances, credits, rebates and other deductions will be fairly and equitably allocated to Licensed Product and other products of \u2587\u2587\u2587\u2587\u2587\u2587\u2587 and its Affiliates and sublicensees such that Licensed Product does not bear a disproportionate portion of such deductions. Sales of a Licensed Product by and between \u2587\u2587\u2587\u2587\u2587\u2587\u2587 and its Affiliates and sublicensees, or between the Parties (or their respective Affiliates, licensees or sublicensees) are not sales to Third Parties and will be excluded from Net Sales calculations; provided, however, that if such Licensed Product is subsequently resold to a Third-Party end user such resale shall be included in the determination of Net Sales. Sales of Licensed Product for the use in conducting Clinical Studies or other scientific testing of Licensed Product in a country will be excluded from Net Sales calculations. Any disposition of the Licensed Product as free samples, donations, patient assistance, test marketing programs or other similar programs or studies will be excluded from Net Sales calculations. Compassionate use and \u201cnamed patient sales\u201d (Early Access Programs) will be excluded from Net Sales calculations. If a Licensed Product is sold as part of a Combination Product in a country, the Parties will negotiate in good faith, at the latest [***] before the expected launch of such Combination Product, an allocation of Net Sales of such Combination Product to its components (i.e., the Licensed Compound or Licensed Product and each of the Other Components), as the case may be, based on the fair market value of such components for the purposes of determining a Licensed Product specific or licensed API specific allocated Net Sales. Payments related to such Combination Product under this Agreement, including royalty payments, will be calculated, due and payable based only on such allocated Net Sales. Without limiting the foregoing and following negotiation, the Parties anticipate that allocated Net Sales will be calculated according to one of the following paradigms with paradigm (i) being more preferable and paradigm (iii) being used only if the information needed to use paradigm (i) or paradigm (ii) is not available: Net Sales with respect to Combination Products for the determination of royalties and Sales Milestone Payments will be calculated by multiplying Net Sales of such Combination Product by the fraction A/(A+B) where A is the average net selling price of the Licensed Product component contained in the Combination Product, if sold separately or subject to reasonable estimation, and B is the sum of the average net selling prices of the API components included in the Combination Product, if sold separately or, if not sold separately, subject to reasonable estimation; Net Sales with respect to Combination Products for the determination of royalties and Sales Milestone Payments will be calculated by multiplying Net Sales of such Combination Product by the fraction A/C where A is the average net selling price of the Licensed Product component in the Combination Product, if sold separately or, if not sold separately, subject to reasonable estimation, and C is the average net selling price of the entire Combination Product; or CERTAIN IDENTIFIED INFORMATION HAS BEEN OMITTED FROM THIS DOCUMENT BECAUSE IT IS BOTH NOT MATERIAL AND WOULD LIKELY CAUSE COMPETITIVE HARM TO THE REGISTRANT IF PUBLICLY DISCLOSED, AND HAS BEEN MARKED WITH \u201c[***]\u201d TO INDICATE WHERE OMISSIONS HAVE BEEN MADE. Net Sales with respect to Combination Products for the determination of royalties and Sales Milestone Payments will be calculated by multiplying Net Sales of such Combination Product by the fraction 1/n where n is the total number of product components (i.e., Licensed Compound or Licensed Product component and Other Component(s)) included in the Combination Product. If the Parties are unable to reach agreement regarding such allocated Net Sales prior to launch of any Combination Product, the calculation of such Licensed Product specific or licensed API specific allocated Net Sales for such Combination Product shall be determined by \u2587\u2587\u2587\u2587\u2587\u2587\u2587 in its reasonable discretion based on one of the paradigms set forth in clauses (i) through (ii) above (or, only if the information needed to use paradigm (i) or paradigm (ii) is not available, based on the paradigm set forth in clause (iii)). Where the foregoing refers to \u201csubject to reasonable estimation\u201d such estimation shall be made by the selling Party and promptly provided to the other Party. If the other Party disagrees with such estimation or, if \u2587\u2587\u2587\u2587\u2587\u2587\u2587 used paradigm (iii), on the appropriateness of which paradigm was used, it shall notify the other Party (\u201cComponent Allocation Notice\u201d) and authorized representatives of each Party shall convene to reasonably determine the proper allocation between the applicable components. If the Parties do not agree on such allocation within [***] of the Component Allocation Notice, then [***]. For clarity, the selling Party may launch such Combination Product and use its reasonable estimation of the average net selling price of each component while such matter is being discussed and until it is resolved in accordance with this Section or Schedule 1.67.", "samples": [{"hash": "4L4MdkCpHRq", "uri": "/contracts/4L4MdkCpHRq#certain-identified", "label": "License Agreement (Contineum Therapeutics, Inc.)", "score": 34.9466119097, "published": true}], "hash": "30b343b85ba2da7b88abdb14489eeaf7", "id": 8}, {"size": 1, "snippet_links": [{"key": "not-material", "type": "clause", "offset": [66, 78]}, {"key": "publicly-disclosed", "type": "definition", "offset": [140, 158]}, {"key": "certain-identified-information-has-been-omitted-from-this-exhibit-because", "type": "clause", "offset": [194, 267]}], "snippet": "INFORMATION HAS BEEN OMITTED FROM THIS EXHIBIT BECAUSE IT IS BOTH NOT MATERIAL AND WOULD LIKELY CAUSE COMPETITIVE HARM TO THE REGISTRANT IF PUBLICLY DISCLOSED. OMISSIONS ARE IDENTIFIED AS [***] CERTAIN IDENTIFIED INFORMATION HAS BEEN OMITTED FROM THIS EXHIBIT BECAUSE IT IS BOTH NOT MATERIAL AND WOULD LIKELY CAUSE COMPETITIVE HARM TO THE REGISTRANT IF PUBLICLY DISCLOSED. OMISSIONS ARE IDENTIFIED AS [***] CERTAIN IDENTIFIED INFORMATION HAS BEEN OMITTED FROM THIS EXHIBIT BECAUSE IT IS BOTH NOT MATERIAL AND WOULD LIKELY CAUSE COMPETITIVE HARM TO THE REGISTRANT IF PUBLICLY DISCLOSED. OMISSIONS ARE IDENTIFIED AS [***] CERTAIN IDENTIFIED INFORMATION HAS BEEN OMITTED FROM THIS EXHIBIT BECAUSE IT IS BOTH NOT MATERIAL AND WOULD LIKELY CAUSE COMPETITIVE HARM TO THE REGISTRANT IF PUBLICLY DISCLOSED. OMISSIONS ARE IDENTIFIED AS [***] CERTAIN IDENTIFIED INFORMATION HAS BEEN OMITTED FROM THIS EXHIBIT BECAUSE IT IS BOTH NOT MATERIAL AND WOULD LIKELY CAUSE COMPETITIVE HARM TO THE REGISTRANT IF PUBLICLY DISCLOSED. OMISSIONS ARE IDENTIFIED AS [***]", "samples": [{"hash": "hSqIevZvHog", "uri": "/contracts/hSqIevZvHog#certain-identified", "label": "Development and Commercialization License Agreement (Opko Health, Inc.)", "score": 31.5790554415, "published": true}], "hash": "a7b03de30610b8601a8d94038c1eb269", "id": 9}, {"size": 1, "snippet_links": [{"key": "not-material", "type": "clause", "offset": [66, 78]}, {"key": "publicly-disclosed", "type": "definition", "offset": [140, 158]}, {"key": "certain-identified-information-has-been-omitted-from-this-exhibit-because", "type": "clause", "offset": [195, 268]}], "snippet": "INFORMATION HAS BEEN OMITTED FROM THIS EXHIBIT BECAUSE IT IS BOTH NOT MATERIAL AND WOULD LIKELY CAUSE COMPETITIVE HARM TO THE REGISTRANT IF PUBLICLY DISCLOSED. OMISSIONS ARE IDENTIFIED AS [***]. CERTAIN IDENTIFIED INFORMATION HAS BEEN OMITTED FROM THIS EXHIBIT BECAUSE IT IS BOTH NOT MATERIAL AND WOULD LIKELY CAUSE COMPETITIVE HARM TO THE REGISTRANT IF PUBLICLY DISCLOSED. OMISSIONS ARE IDENTIFIED AS [***]. CERTAIN IDENTIFIED INFORMATION HAS BEEN OMITTED FROM THIS EXHIBIT BECAUSE IT IS BOTH NOT MATERIAL AND WOULD LIKELY CAUSE COMPETITIVE HARM TO THE REGISTRANT IF PUBLICLY DISCLOSED. OMISSIONS ARE IDENTIFIED AS [***].", "samples": [{"hash": "36z7d0Yuxov", "uri": "/contracts/36z7d0Yuxov#certain-identified", "label": "Master Agreement (Nuvo Group Ltd.)", "score": 32.8932238193, "published": true}], "hash": "25527144b1e1fa9c364173f2360b229e", "id": 10}], "next_curs": "ClsSVWoVc35sYXdpbnNpZGVyY29udHJhY3RzcjcLEhZDbGF1c2VTbmlwcGV0R3JvdXBfdjU2IhtjZXJ0YWluLWlkZW50aWZpZWQjMDAwMDAwMGEMogECZW4YACAA", "clause": {"parents": [], "children": [], "size": 10, "title": "CERTAIN IDENTIFIED", "id": "certain-identified", "related": [["if-identified", "If Identified", "If Identified"], ["non-identification", "Non-Identification", "Non-Identification"], ["separate-identity", "Separate Identity", "Separate Identity"], ["customer-identification", "Customer Identification", "Customer Identification"], ["customer-identification-program", "Customer Identification Program", "Customer Identification Program"]], "related_snippets": [], "updated": "2025-07-07T12:37:40+00:00"}, "json": true, "cursor": ""}}